Androgen receptors in breast cancer.
Androgen receptor assays have been performed on 1371 specimens of histologically confirmed primary and recurrent breast cancer. Forty-two patients who had received tamoxifen as treatment for advanced disease were assessed for objective response. Another 42 patients who had received chemotherapy were similarly studied. Patients with androgen receptor-negative tumors had a significantly poorer response rate to hormone therapy than those with receptor-positive tumors (P less than 0.05). This clinical correlation is supported by survival data of 1181 patients with primary breast cancer which showed that patients with androgen receptor-negative tumors had a highly significant trend toward shorter overall survival than those with receptor-positive tumors (P less than 0.001). Androgen receptor data added significantly to the information provided by estrogen receptor data both in terms of response to hormone treatment and survival.
D001943:Breast Neoplasms / Q000032:analysis* / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008593:Menopause; D009362:Neoplasm Metastasis; D011379:Prognosis; D011944:Receptors, Androgen / Q000032:analysis* / Q000187:drug effects; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects; D011987:Receptors, Steroid / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011987:Receptors, Steroid; D013629:Tamoxifen